Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New shareholder

<< Previous

Bullboard Posts

Next >>

Comment by spesestsemperon Apr 18, 2024 8:38pm

127 Views

Post# 35997136

RE:RE:RE:RE:RE:RE:RE:RE:RE:New shareholder

Im not here to ruffle any feathers but I just dont see the math on getting a multi billion dollar deal . The aquiring company is taking a lot of risks of something getting delayed and the time to market . Hence i see the lower buyout price . My fear is that they try to do things on a shoe string and just keep drawing things out for a long time . Insight is a funny thing - hindsight is usually right .

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record